Señales en vivo de MLND | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 jun 2021 @ 00:00):

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States...

Stats
Volumen de hoy	1.91M
Volumen promedio	140 975
Capitalización de mercado	11.15M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0940 (8.87%)

Insider Trading

Date	Person	Action	Amount	type
2020-06-22	Nuechterlein Carole	Buy	12 000	Stock Option (right to buy)
2020-06-22	Howe John P Md	Buy	12 000	Stock Option (right to buy)
2020-06-22	Gallagher Carol Giltner	Buy	12 000	Stock Option (right to buy)
2020-06-22	Nichol Geoffrey	Buy	12 000	Stock Option (right to buy)
2020-06-22	Hindman James M.	Buy	12 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 34 transactions
Buy: 816 539 \| Sell: 0

Volumen Correlación

Largo: -0.37 (neutral)

Corto: 0.79 (moderate)

Signal:(35.927) Neutral

Millendo Therapeutics Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Millendo Therapeutics Inc Correlación - Moneda/Commodity

0.64
( weak )

-0.17
( neutral )

0.00
( neutral )

0.44
( neutral )

-0.68
( moderate negative )

-0.61
( weak negative )

Millendo Therapeutics Inc Finanzas

Annual	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-28.95

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-28.95

FY	2019
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-48.75

FY	2018
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-263.70

Financial Reports:

No articles found.

Millendo Therapeutics Inc

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.